Niklas Mueller
Research Subjects
Research Interests
Niklas Mueller has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Peter Valent
Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, 1090 Vienna, Austria
4 shared publications Wolfgang R. Sperr
Ludwig Boltzmann Institute for Hematology and Oncology
4 shared publications- Gregor Hoermann
MLL Munich Leukemia Laboratory, Munich, Germany
3 shared publications Daniel Wicklein
Institute of Anatomy and Experimental Morphology, University Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
2 shared publications- Gabriele Stefanzl
Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
2 shared publications Gregor Eisenwort
Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Austria; Ludwig Boltzmann Institute for Hematology & Oncology, Medical University of Vienna, Austria
2 shared publications
Latest Publications
- Open Access
- 21 October 2020
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (20) , 5118-5132
Delineation of target expression profiles in CD34+/CD38− and CD34+/CD38+ stem and progenitor cells in AML and CML
In an attempt to identify novel markers and immunological targets in leukemic stem cells (LSCs) in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), we screened bone marrow (BM) samples from patients with AML (n = 274) or CML (n = 97) and controls (n = 288) for expression of cell membrane antigens on CD34+/CD38− and CD34+/CD38+ cells by multicolor flow cytometry. In addition, we established messenger RNA expression profiles in purified sorted CD34+/CD38− and CD34+/CD38+ cells using gene array and quantitative polymerase chain reaction. Aberrantly expressed markers were identified in all cohorts. In CML, CD34+/CD38− LSCs exhibited an almost invariable aberration profile, defined as CD25+/CD26+/CD56+/CD93+/IL-1RAP+. By contrast, in patients with AML, CD34+/CD38− cells variably expressed “aberrant” membrane antigens, including CD25 (48%), CD96 (40%), CD371 (CLL-1; 68%), and IL-1RAP (65%). With the exception of a subgroup of FLT3 internal tandem duplication–mutated patients, AML LSCs did not exhibit CD26. All other surface markers and target antigens detected on AML and/or CML LSCs, including CD33, CD44, CD47, CD52, CD105, CD114, CD117, CD133, CD135, CD184, and roundabout-4, were also found on normal BM stem cells. However, several of these surface targets, including CD25, CD33, and CD123, were expressed at higher levels on CD34+/CD38− LSCs compared with normal BM stem cells. Moreover, antibody-mediated immunological targeting through CD33 or CD52 resulted in LSC depletion in vitro and a substantially reduced LSC engraftment in NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice. Together, we have established surface marker and target expression profiles of AML LSCs and CML LSCs, which should facilitate LSC enrichment, diagnostic LSC phenotyping, and development of LSC-eradicating immunotherapies.
- 21 October 2020
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (20) , 5118-5132
Open AccessDelineation of target expression profiles in CD34+/CD38− and CD34+/CD38+ stem and progenitor cells in AML and CML
In an attempt to identify novel markers and immunological targets in leukemic stem cells (LSCs) in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), we screened bone marrow (BM) samples from patients with AML (n = 274) or CML (n = 97) and controls (n = 288) for expression of cell membrane antigens on CD34+/CD38− and CD34+/CD38+ cells by multicolor flow cytometry. In addition, we established messenger RNA expression profiles in purified sorted CD34+/CD38− and CD34+/CD38+ cells using gene array and quantitative polymerase chain reaction. Aberrantly expressed markers were identified in all cohorts. In CML, CD34+/CD38− LSCs exhibited an almost invariable aberration profile, defined as CD25+/CD26+/CD56+/CD93+/IL-1RAP+. By contrast, in patients with AML, CD34+/CD38− cells variably expressed “aberrant” membrane antigens, including CD25 (48%), CD96 (40%), CD371 (CLL-1; 68%), and IL-1RAP (65%). With the exception of a subgroup of FLT3 internal tandem duplication–mutated patients, AML LSCs did not exhibit CD26. All other surface markers and target antigens detected on AML and/or CML LSCs, including CD33, CD44, CD47, CD52, CD105, CD114, CD117, CD133, CD135, CD184, and roundabout-4, were also found on normal BM stem cells. However, several of these surface targets, including CD25, CD33, and CD123, were expressed at higher levels on CD34+/CD38− LSCs compared with normal BM stem cells. Moreover, antibody-mediated immunological targeting through CD33 or CD52 resulted in LSC depletion in vitro and a substantially reduced LSC engraftment in NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice. Together, we have established surface marker and target expression profiles of AML LSCs and CML LSCs, which should facilitate LSC enrichment, diagnostic LSC phenotyping, and development of LSC-eradicating immunotherapies.
- 1 February 2020
- Published by Elsevier in Seminars in Cancer Biology
- Vol. 60, 191-201
Redistribution, homing and organ-invasion of neoplastic stem cells in myeloid neoplasms
- 1 February 2020
- Published by Elsevier in Seminars in Cancer Biology
- Vol. 60, 191-201
Redistribution, homing and organ-invasion of neoplastic stem cells in myeloid neoplasms
- Open Access
- 17 July 2018
- Published by American Society of Hematology in Blood
- Vol. 132 (18) , 1936-1950
CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis
Key Points: CD44 is a RAS/STAT5-dependent target in neoplastic mast cells and correlates with aggressiveness of mastocytosis. Depletion of CD44 in neoplastic mast cells is associated with reduced invasion and prolonged survival in SCID mice.
- 17 July 2018
- Published by American Society of Hematology in Blood
- Vol. 132 (18) , 1936-1950
Open AccessCD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis
Key Points: CD44 is a RAS/STAT5-dependent target in neoplastic mast cells and correlates with aggressiveness of mastocytosis. Depletion of CD44 in neoplastic mast cells is associated with reduced invasion and prolonged survival in SCID mice.
- Open Access
- 27 April 2017
- Published by Elsevier in Experimental Hematology
- Vol. 51, 17-24
Expression of CD25 on leukemic stem cells in BCR-ABL1+ CML: Potential diagnostic value and functional implications
- 27 April 2017
- Published by Elsevier in Experimental Hematology
- Vol. 51, 17-24
Open AccessExpression of CD25 on leukemic stem cells in BCR-ABL1+ CML: Potential diagnostic value and functional implications